Premium
Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients
Author(s) -
Chang TingTing,
Wu TaoCheng,
Huang PoHsun,
Chen JiaShiong,
Lin LiangYu,
Lin ShingJong,
Chen JawWen
Publication year - 2016
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12632
Subject(s) - aliskiren , progenitor cell , endothelial progenitor cell , vascular endothelial growth factor , stromal cell , transfection , chemistry , endocrinology , endothelial stem cell , medicine , renin–angiotensin system , biology , in vitro , stem cell , vegf receptors , microbiology and biotechnology , biochemistry , gene , blood pressure
Background Endothelial progenitor cell ( EPC ) functions are impaired in the presence of diabetes mellitus. Aliskiren is a direct renin inhibitor, which is expected to modify proangiogenic cells. This study aimed to investigate whether and how aliskiren could improve the function of EPC s from patients with type II diabetes (T2 DM ). Materials and methods Endothelial progenitor cells fibronectin adhesion assay, chamber assay and in vitro tube formation assay were used to estimate the degree of EPC adhesion, migration and tube formation abilities. EPC protein and mRNA expressions were evaluated by Western blot and quantitative RT ‐ PCR , respectively. EPC vascular endothelial growth factor ( VEGF ) and (pro)renin receptor ((P) RR ) expression was knocked down by VEGF and (P) RR si RNA . Results Aliskiren (0·1 or 10 μM) dose‐dependently improved functions and increased both VEGF and stromal cell‐derived factor‐1α ( SDF ‐1α) expression of EPC s from patients with T2 DM or EPC s from healthy volunteers and treated with high glucose. Transfection with VEGF si RNA significantly reduced the aliskiren‐induced SDF ‐1α expression. Furthermore, (P) RR si RNA transfection impaired the aliskiren‐induced VEGF and SDF ‐1 expression. Conclusions The results show that aliskiren improved EPC function from patients with T2 DM in a dose‐dependent manner probably via the (P) RR and VEGF / SDF ‐1α‐related mechanisms.